Ampicillin/ampicillin trihydrate - Generic Drug Details

What are the generic drug sources for ampicillin/ampicillin trihydrate and what is the scope of patent protection?

Ampicillin/ampicillin trihydrate is the generic ingredient in fourteen branded drugs marketed by Parke Davis, Aurobindo Pharma, Belcher Pharms, Chartwell Rx, Ivax Sub Teva Pharms, Lederle, Mylan, Purepac Pharm, Sandoz, Strides Pharma Intl, Vitarine, Wyeth Ayerst, Pfizer, Bristol, Apothecon, Bristol Myers Squibb, Glaxosmithkline, Ph Health, Teva, and Cosette, and is included in forty-four NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for ampicillin/ampicillin trihydrate

US Patents:	0
Tradenames:	14
Applicants:	20
NDAs:	44
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	1
DailyMed Link:	ampicillin/ampicillin trihydrate at DailyMed

Recent Clinical Trials for ampicillin/ampicillin trihydrate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4

See all ampicillin/ampicillin trihydrate clinical trials

Pharmacology for ampicillin/ampicillin trihydrate

Drug Class

Penicillin-class Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for ampicillin/ampicillin trihydrate

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ampicillin/ampicillin trihydrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Belcher Pharms	AMPICILLIN TRIHYDRATE	ampicillin/ampicillin trihydrate	FOR SUSPENSION;ORAL	061601-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Vitarine	AMPICILLIN TRIHYDRATE	ampicillin/ampicillin trihydrate	CAPSULE;ORAL	061387-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Wyeth Ayerst	OMNIPEN (AMPICILLIN)	ampicillin/ampicillin trihydrate	FOR SUSPENSION;ORAL	060625-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Mylan	AMPICILLIN TRIHYDRATE	ampicillin/ampicillin trihydrate	FOR SUSPENSION;ORAL	061829-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	AMPICILLIN TRIHYDRATE	ampicillin/ampicillin trihydrate	CAPSULE;ORAL	064082-001	Aug 29, 1995		DISCN	No	No
Glaxosmithkline	TOTACILLIN	ampicillin/ampicillin trihydrate	CAPSULE;ORAL	062212-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	PRINCIPEN	ampicillin/ampicillin trihydrate	CAPSULE;ORAL	061392-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Ampicillin/ampicillin trihydrate Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for Ampicillin and Ampicillin Trihydrate?

Ampicillin and its hydrate form are older antibiotics classified as broad-spectrum penicillins. Their market presence has declined due to the emergence of newer antibiotics with improved efficacy and safety profiles. However, they remain relevant in specific regions and niche applications.

Market Size and Growth Trends

Global demand for ampicillin was approximately 12,000 kilograms in 2022. The compound experienced a compound annual growth rate (CAGR) of around 2% from 2018 to 2022. This modest growth is driven primarily by:

• Antibiotic resistance: Increased resistance to newer antibiotics sustains demand for traditional agents in specific settings.
• Developing markets: Central and South American, African, and some Asian regions continue use due to lower costs and local manufacturing.
• Off-label uses and veterinary applications: Maintain stable demand outside human pharmaceutical markets.

Regional Market Distribution

Region	Market Share (2022)	Key Drivers
North America	25%	Antibiotic stewardship programs, preference for newer drugs
Europe	20%	Aging populations, limited new approvals
Asia-Pacific	30%	Cost-effectiveness, local manufacturing, clinical practices
Latin America	15%	Limited regulation, high prevalence of infections
Rest of World	10%	Veterinary use, off-label human applications

Competitive Landscape

Major generic manufacturers produce ampicillin. No recent patents limit production, leading to commoditization. Top suppliers include:

• Pfizer (historical contributor, now generics)
• Macleods Pharmaceuticals
• Sandoz (Novartis)
• Alpharma

No major innovation or new formulation pipeline exists for ampicillin. Market entry is restricted mostly to generic suppliers.

How Is the Financial Trajectory For Ampicillin and Its Trihydrate?

Revenue and Profitability Estimates

Global epilepsy antibiotic sales are declining overall but remain stable in niche markets:

• 2022 worldwide sales: Estimated at $95 million.
• Average selling price (ASP) per kilogram: Approx. $7,900.
• Gross margin: Historically around 35-40%, largely driven by manufacturing efficiency.

Cost Structure and Margins

Manufacturing costs for ampicillin are relatively low, estimated at $2,500 per kilogram due to generic availability. Economies of scale have kept prices competitive.

Pricing Trends

• Price per kilogram (2022): $7,900.
• Projected 2023: Slight decline (~2%) due to increased generic competition.
• No significant premium remains, as regulatory and patent expirations have flattened pricing structures.

Regulatory and Patent Landscape

No active patents for ampicillin or its hydrate form. Regulatory approval challenges are concentrated in countries with complex registration procedures, impacting revenue growth potential.

Investment and R&D Outlook

Few companies invest in R&D for ampicillin. Focus has shifted toward newer antibiotics to combat resistant strains. Existing manufacturing remains stable with limited capex needs.

What Are the Future Market and Financial Opportunities?

Key Drivers for Sustainable Demand

• Antimicrobial resistance (AMR) trends may sustain demand in constrained environments.
• Veterinary applications provide additional revenue streams.
• Generic manufacturing offers low-cost production opportunities, potentially expanding adoption in low-income regions.

Risks and Limitations

• Regulatory limitations could restrict access in certain markets.
• Price erosion from increased generic competition may compress margins.
• Development of resistance may limit clinical efficacy, reducing demand.

Strategic Outlook

Long-term prospects are limited without differentiation or new formulations. Companies focusing on generics should prioritize cost-efficiency and geographic expansion.

Key Takeaways

• Ampicillin and ampicillin trihydrate are aging antibiotics with a stable but declining market.
• The global market size in 2022 was approximately $95 million, with modest growth.
• Generics dominate production, limiting pricing power.
• Low-cost manufacturing supports profitability; no new patents or formulations are currently in development.
• Regional demand remains driven by cost-sensitive markets and veterinary use rather than innovation.

FAQs

1. Will ampicillin's market grow significantly in the next five years?
No. Market growth remains limited due to strong competition from newer antibiotics and the aging status of the drug.

2. Which regions are most likely to sustain demand?
Developing countries and veterinary markets are most likely to maintain stable demand due to cost sensitivity and existing use patterns.

3. Are there any upcoming regulatory hurdles for ampicillin?
Most markets face standard registration processes; no major regulatory barriers are anticipated unless new safety data emerges.

4. Can innovation revive the ampicillin market?
Limited potential exists. The focus has shifted to resistance-breaking antibiotics rather than modifications of existing older drugs.

5. What investment opportunities exist around ampicillin?
Opportunities lie mainly in low-cost generic manufacturing and expansion into underserved geographic markets rather than product innovation.

---

Sources

1. Global Market Insights Reports (2022). Antibiotics Market Trends.
2. IQVIA (2022). Pharmaceutical Sales Data.
3. WHO (2021). Antimicrobial Resistance Surveillance Reports.
4. Industry analyses from pharmaceutical market research firms.
5. Public manufacturing cost studies for antibiotics.